Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Theravance
Biotech
Phase 3 rare disease failure extends Theravance's losing streak
Theravance added another failure to its portfolio when it disclosed a phase 3 flop in a blood pressure disorder, but is yet to give up on the drug.
Nick Paul Taylor
Apr 5, 2022 9:00am
Theravance axing 75% of staff after flunking phase 3
Sep 15, 2021 8:10am
Up-and-coming JAK inhibitors face 'shrinking' potential
Sep 7, 2021 9:30am
Theravance, J&J's phase 2b ulcerative colitis trial fails
Aug 23, 2021 5:04pm
Frontier launches with biotech vet CEO—Chutes & Ladders
Jun 28, 2019 9:30am
Recursion names Theravance veteran as CSO
Jun 21, 2019 8:55am
